PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
A higher number corresponds to a larger, more complex capsid. Zandi and her colleagues used a new simulation framework to capture key biological factors like protein diffusion, genome flexibility, and ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
Morning Overview on MSN
Scientists just mapped how a common class of viruses pries open human cells — the same break-in move behind polio, heart inflammation, and the common cold
A team led by structural biologists at the University of Maryland, Baltimore County has produced the most detailed picture ...
Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host ...
The two-component cage, pictured here, is made of protein homotrimers (red) and linkers (blue). Credit: Shunzhi Wang Genetic medicines, like those based on CRISPR/Cas9, need a delivery method to reach ...
The efficacy of adeno-associated virus (AAV)-mediated gene therapy for the inner ear is fundamentally constrained by the natural tropism of viral vectors, which often lack the precision and efficiency ...
CMS College researchers developed SPHAK, a model predicting cross-species virus transmission with over 97% accuracy using viral protein analysis.
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results